Gilman Hill Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gilman Hill Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,000	Closed	-$216K	–	227
2021 Q4	$216K	Hold	2,000	–	–	0.05%	206
2021 Q3	$219K	Buy	+2,000	New	+$208K	0.06%	191

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilman Hill Asset Management's HZNP Position: Q1 2022 in Review

Gilman Hill Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 2,000 shares — an estimated $216K sold.

Gilman Hill Asset Management first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $219K in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Gilman Hill Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Gilman Hill Asset Management sold 2,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $216K.
Gilman Hill Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
Gilman Hill Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $219K in Q3 2021.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Gilman Hill Asset Management's 13F filing for Q1 2022, filed 14 Apr 2022.